Feb 6 |
Theratechnologies to Announce Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update
|
Jan 31 |
Positive Signs As Multiple Insiders Buy Theratechnologies Stock
|
Jan 24 |
Theratechnologies Receives Complete Response Letter (CRL) from the FDA for the F8 Formulation of Tesamorelin sBLA
|
Jan 23 |
Theratechnologies Receives Update from FDA on Tesamorelin F8 Supplemental Biologic License Application
|
Jan 2 |
Theratechnologies Submits sBLA for Trogarzo® Intramuscular (IM) Method of Administration to FDA
|
Dec 21 |
Theratechnologies Announces Renewal of Shelf Prospectus and Filing of Registration Statement
|
Dec 13 |
Theratechnologies Announces FDA Approval of Trogarzo® 90-Second Intravenous (IV) Push Loading Dose
|
Nov 24 |
Theratechnologies Receives 2023 CQDM ADRIQ RSRI Innovation Award
|